Home > News > First Protein-Bound Nanoparticle Breast Cancer Drug
January 7th, 2005
First Protein-Bound Nanoparticle Breast Cancer Drug
Abstract:
Researchers at Lynn Sage Comprehensive Breast Center played a significant role in the U.S. Food and Drug Administration (FDA) approval of ABRAXANE(TM) (paclitaxel protein bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.
"This approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel.
Source:
prnewswire
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||